Asuragen, Inc., a global molecular diagnostics company, will be presenting extensive new scientific and clinical studies at the upcoming Association for Molecular Pathology (AMP) annual meeting, November 10 - 12, 2016 in Charlotte, NC. The presentations by Asuragen scientists and collaborators will cover a broad range of topics, from their latest technology discoveries to advances in genetic disease testing, oncology disease monitoring and NGS profiling of solid and liquid biopsies.
“Our company is focused on delivering innovative molecular solutions to unmet clinical needs in oncology and genetics. The AMP annual meeting provides us with the forum to share our many exciting and groundbreaking clinical and scientific advances from the past 12 months and to continue to demonstrate our commitment to being a leader in oncology and genetics,” said Matthew McManus, M.D., Ph.D., Asuragen’s President and CEO.
At the 2016 AMP annual meeting, Asuragen will host two corporate workshops - one on the newly FDA-cleared BCR-ABL monitoring assay for chronic myeloid leukemia (CML) and a second focused on the performance characteristics and usability of the recently launched QuantideX® NGS RNA Lung Cancer Kit (RUO). In addition, nine scientific posters will highlight recent scientific and clinical findings.
The first workshop will feature presentations by Christopher D. Watt, M.D., Ph.D., Associate Director, Molecular Pathology Laboratory, University of Pennsylvania, Perlman School of Medicine, and Bernard Andruss, Ph.D., Vice President of Diagnostic Development at Asuragen. They will focus on the QuantideX® qPCR BCR-ABL IS Kit and will cover topics ranging from analytical validation data and real-world workflow experience to the clinical implications of using a BCR-ABL minimal residual disease monitoring kit with unprecedented sensitivity (MR4.7) in Chronic Myeloid Leukemia (CML).
In the second workshop, Léon C. van Kempen, Ph.D., Chief Operating Officer & Scientific Director, Dubrovsky Molecular Pathology Centre, Jewish General Hospital, and Gary Latham, Ph.D. Vice President, Research & Technology Development, Asuragen, will present on a routine laboratory’s experience evaluating the QuantideX® NGS RNA Lung Cancer Kit (RUO), analytical sensitivity data, information from a multi-site evaluation and how the integrated, Sample-Aware™ bioinformatics software improves results quality and minimizes sample failures.
Asuragen’s products and technologies are also being featured in nine scientific posters across multiple topics. The breadth of this scientific output from Asuragen reflects the company’s drive to deliver innovative clinical and research solutions that address many current challenges in genetics and oncology. The posters being presented at the conference are:
Poster Session: Friday, November 11 from 2:30 – 3:30 PM
Poster Session: Saturday, November 12 from 9:45 – 10:45 AM
*For Research Use Only. Not for use in diagnostic procedures
For more information on Asuragen’s activities at the 2016 AMP annual meeting, visit www.asuragen.com/AMP16 or stop by booth #1219.
Asuragen is a global diagnostic products company delivering solutions that build knowledge and understanding of complex clinical questions. Asuragen’s application of its deep scientific heritage and molecular expertise delivers diagnostic products in oncology and genetics that provide the best answers with optimal workflows – so time can be spent delivering actionable insights, rather than searching for them. With innovative approaches to kit development and a broad range of molecular chemistries, Asuragen produces assays that ensure reproducible results. From discovery to regulatory support to global commercialization, we provide a customizable approach that efficiently delivers custom and companion diagnostic products for our partners. We believe people deserve better answers. For more information, visit www.asuragen.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161108005317/en/Business Wire
Last updated on: 08/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.